Page 64 - EJMO-9-2

Eurasian Journal of
Medicine and Oncology TCM regulates gut microbiota in pediatric MP pneumonia

conclusions potentially subjective; (v) the difficulty in Availability of data
publishing negative results suggests a potential publication
bias; and (vi) the methodology and quality of many The article and accompanying supplementary material
included studies were suboptimal, necessitating further provide a comprehensive overview of the original findings
from this study. Any questions or inquiries can be directed
improvements.
to the corresponding author.
5. Conclusion
References
Treatment with Chinese medicine resulted in an increase 1. Narita M. Pathogenesis of extrapulmonary manifestations of
in the number of Bifidobacteria and Lactobacilli in the Mycoplasma pneumoniae infection with special reference to
intestines of children with MPP, while reducing the pneumonia. J Infect Chemother. 2010;16(3):162-169.
number of harmful bacteria, thereby improving the
microecological environment of intestinal microbiota. doi: 10.1007/s10156-010-0044-x
Furthermore, the incidence of adverse reactions was 2. Kumar S, Kumar S. Mycoplasma pneumoniae: Among the
lower. Therefore, in clinical practice, the intestinal smallest bacterial pathogens with great clinical significance
microbiota of children with MPP can be regulated in children. Indian J Med Microbiol. 2023;46:100480.
through the multifaceted effects of TCM to maintain doi: 10.1016/j.ijmmb.2023.100480
immune homeostasis, especially when combined 3. Zhu Y, Luo Y, Li L, et al. Immune response plays a role in
with Western medical treatments to enhance clinical Mycoplasma pneumoniae pneumonia. Front Immunol.
effectiveness. However, this study has several limitations, 2023;14:1189647.
and its results should be viewed as a reference for clinical doi: 10.3389/fimmu.2023.1189647
treatment. Therefore, large-sample, high-quality RCTs
are necessary to validate these findings and provide more 4. Waites KB, Talkington DF. Mycoplasma pneumoniae
reliable evidence for clinical practice. and its role as a human pathogen. Clin Microbiol Rev.
2004;17(4):697-728, table of contents.
Acknowledgments doi: 10.1128/CMR.17.4.697-728.2004

None. 5. Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric
Mycoplasma pneumoniae pneumonia in North China: 2006
Funding to 2016. Epidemiol Infect. 2019;147:e192.

This research was supported by the Tianjin Municipal doi: 10.1017/S0950268819000839
Education Commission Scientific Research Program 6. Feng, Xue-Li, Li, Q.J., Sun, L., et al. A case-control study
Project (Natural Science) Key Project (No. 2021ZD024). of the clinical characteristics of macrolide-resistant and
sensitive Mycoplasma pneumoniae. Chin J Evid Based
Conflict of interest Paediatr. 2016;11(5):357-360.

The authors declare that they have no relevant financial 7. Lee H, Yun KW, Lee HJ, Choi EH. Antimicrobial therapy of
interests or personal relationships that could influence the macrolide-resistant Mycoplasma pneumoniae pneumonia in
objectivity of the research presented in this paper. children. Expert Rev Anti Infect Ther. 2018;16(1):23-34.
Author contributions doi: 10.1080/14787210.2018.1414599
8. Guo L, Wang J. Clinical prevention of gastrointestinal adverse
Conceptualization: Weiwei Liu reactions to macrolide antibiotics in children. In: Proceedings
Writing–original draft: Keke Li of the 2017 International Digital Medical Society Conference
Writing–review & editing: Qinghe Zeng, Jianyi Liu, Yueyu on Digital Traditional Chinese Medicine. Lanzhou, China:
Ma, Weiwei Liu Lanzhou General Hospital of Lanzhou Military Region,
Department of Pediatrics; Hunan University of Chinese
Ethics approval and consent to participate Medicine Journal Press; 2017. p. 444-445.
Not applicable. 9. Ling Z, Liu X, Guo S, et al. Role of probiotics in Mycoplasma
pneumoniae pneumonia in children: A short-term pilot
Consent for publication project. Front Microbiol. 2018;9:3261.
Not applicable. doi: 10.3389/fmicb.2018.03261

Volume 9 Issue 2 (2025) 56 doi: 10.36922/ejmo.8602